SCORAD Index: Unified assessment of Atopic Dermatitis severity.
Affected Area (A)
No InvolvementFull Body
Intensity Factors (B)
erythema
edema
crusting
excoriation
lichenification
dryness
Subjective Symptoms (C)
0/10
NoneSevere
0/10
NoneSevere
Awaiting Assessment
Enter the area involvement, intensity of signs, and subjective symptoms to calculate the total SCORAD index.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
SCORAD is a composite severity index for atopic dermatitis (AD) developed by the European Task Force on Atopic Dermatitis (ETFAD). It combines a clinician-assessed extent score, an intensity score across six morphological signs, and two patient-reported subjective symptoms (itch and sleep loss). It remains the most comprehensive single-instrument measure of AD severity and is widely used in European clinical practice and trials.
Primary Indications
Baseline AD severity assessment before initiating systemic therapy
Longitudinal monitoring of treatment response in clinical trials and specialist practice
Regulatory clinical trials — SCORAD is accepted as a secondary or primary endpoint in EMA submissions
Research settings requiring a composite, validated measure capturing both objective signs and subjective symptoms
When NOT to Use
Non-AD eczemas — validated only for atopic dermatitis, not contact dermatitis or seborrhoeic dermatitis
How it Works
SCORAD Formula
SCORAD = (A/5) + (7 × B/2) + C. Maximum total score = 103. A = Extent (0–100); B = Intensity (0–18); C = Subjective symptoms (0–20).
Component A — Extent of Involvement
The percentage of body surface area (BSA) affected by active AD lesions is estimated using the Rule of Nines (adults) or a modified chart (children). Only areas with active lesions are counted; post-inflammatory hyperpigmentation alone is not scored. Score range: 0–100%.
Component B — Intensity (6 Signs, each 0–3)
| Erythema | 0 = absent | 1 = mild | 2 = moderate | 3 = severe |
| Edema / Papulation | 0 = absent | 1 = mild | 2 = moderate | 3 = severe |
| Oozing / Crusting | 0 = absent | 1 = mild | 2 = moderate | 3 = severe |
| Excoriations | 0 = absent | 1 = mild | 2 = moderate | 3 = severe |
| Lichenification | 0 = absent | 1 = mild | 2 = moderate | 3 = severe |
| Dryness (xerosis) | 0 = absent | 1 = mild | 2 = moderate | 3 = severe — assessed on UNINVOLVED skin only |
Component C — Subjective Symptoms (Patient VAS, each 0–10)
Pruritus (itch) intensity: Patient marks on a 10 cm VAS for the past 3 days/nights
Sleep disturbance: Patient marks on a 10 cm VAS for the past 3 nights
Combined C score = sum of both VAS scores (max 20)
Clinical Pearls
Key Advantages
SCORAD is the only widely used AD severity instrument that integrates both objective clinical signs and patient-reported subjective symptoms (itch + sleep) in a single composite score.
Dryness is uniquely assessed on uninvolved skin — this captures baseline skin barrier dysfunction independent of active inflammation, which correlates with disease chronicity and relapse risk.
Strong correlation with treatment response biomarkers (TARC/CCL17, IgE) in dupilumab and other biologic trials.
Available as an app-based tool (eSCORAD) validated against the paper version for use in telemedicine settings.
Limitations
More time-consuming than EASI or IGA; requires patient VAS completion and BSA estimation — typically 8–12 minutes in clinical practice.
Inter-rater reliability for intensity grading is moderate without formal training; the ETFAD recommends assessor calibration in research settings.
The relative weighting of components (A/5, 7B/2, C) was derived empirically rather than from formal psychometric analysis — critics argue the weights undervalue extent.
Comparator Instruments
| EASI | Clinician-assessed only; no subjective component; 4 regions × 4 signs. Preferred FDA endpoint. Faster than SCORAD. |
| POEM | Patient-reported only; 7 items; 7-day recall. Endorsed by NICE for biologic eligibility in UK. |
| IGA (0–4) | Fastest clinician global assessment; binary (clear/almost clear) for trial endpoints. |
| oSCORAD | SCORAD minus subjective component C — preferred when PRO separation is required. |
Next Steps
Management by SCORAD
| SCORAD < 25 (Mild) | Regular emollients (minimum 250 g/week for adults). Reactive low-to-mid potency topical corticosteroid (TCS) or topical calcineurin inhibitor (TCI) for flares. Written action plan. |
| SCORAD 25–50 (Moderate) | Optimize topical therapy: step up TCS potency; proactive TCS/TCI maintenance on flare-prone sites. Consider phototherapy (NB-UVB) if extensive. Dermatology referral. |
| SCORAD > 50 (Severe) | Specialist review. Consider short-course ciclosporin for rapid control. Evaluate for biologic eligibility (dupilumab, tralokinumab, lebrikizumab). Assess for triggers, secondary infection, psychological comorbidity. |
Response Benchmarks
01
Document baseline SCORAD before initiating any new systemic or biologic therapy
02
Reassess at 4 and 16 weeks — a SCORAD reduction of ≥ 8.7 points is the published MCID
03
At 16 weeks on dupilumab: expect mean SCORAD reduction of ~40–50% from baseline in responders
04
Continue therapy if SCORAD < 50% of baseline (meaningful response); re-evaluate if inadequate
The Evidence
Original Derivation
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis.
European Task Force on Atopic Dermatitis. • Dermatology. 1993;186(1):23-31. Derivation and consensus report establishing the SCORAD formula, component weights, and scoring methodology.
View SourceExternal Links
Origins & History
Origins
SCORAD was developed by the European Task Force on Atopic Dermatitis (ETFAD) — a multinational consortium of European dermatologists — and published in Dermatology in 1993. The Task Force sought to create a comprehensive, reproducible instrument that combined objective clinical assessment with patient-reported symptom burden, addressing the limitations of purely clinician-rated scales. The formula weighting (A/5 for extent, 7B/2 for intensity, C for subjective symptoms) was derived through mathematical modelling to ensure each domain contributed approximately equally to the total score. SCORAD became the dominant European AD assessment tool and remains central to continental European guideline recommendations and regulatory submissions, while EASI is more commonly used as the primary endpoint in North American FDA submissions.
Last Comprehensive Review: 2026-07-17